Company: CLX
Filing Date: 2025-10-07
Form Type: DEF 14A
Source: 0001552781-25-000311
Chunk: 68

Company: CLOROX CO /DE/
Filing Date: 2025-10-07
Form: DEF 14A
Chunk 68
---
 sales were 3.1% and 3.0% for fiscal years 2025 and 2024, respectively. Free cash flow

|                                        |  2025 | 2024 |
| Net                                    
 cash provided by operations            |     $ 
   981 |    $ 
  695 |
| Less:                                  
 capital expenditures                   |  -220 | -212 |
| Free                                   
 cash flow                              |     $ 
   761 |    $ 
  483 |
| Free                                   
 cash flow as a percentage of net sales | 10.7% | 6.8% |

Financing Activities Net cash used for financing activities was $924 in fiscal year 2025, compared with $655 in fiscal year 2024. The year-over-year increase was mainly due to higher treasury stock purchases in the current year. Capital Resources and Liquidity As of June 30, 2025, current liabilities exceeded current assets by $311, primarily due to the Company’s Glad venture agreement terminal obligation coming due for payment in January 2026. This liability was reclassified from Other liabilities to Accounts payable and accrued liabilities as it is reasonably expected to be settled within one year. The venture agreement terminal obligation is expected to be repaid through the Company’s anticipated ability to generate positive cash flows from operations in the future, access to capital markets enabled by our strong short-term and long-term credit ratings and current borrowing availability. See Notes to Consolidated Financial Statements for further information on the Glad venture agreement. Notwithstanding potential unforeseen adverse market conditions and as part of the Company’s regular assessment of its cash needs, the Company believes it will have the funds necessary to support its short- and long-term liquidity and operating needs, including its digital capabilities and productivity enhancements investment and venture agreement terminal obligation based on its anticipated ability

| The                                              
 Clorox Company 2025 Proxy Statement > Appendix A | A-9 |

to generate positive cash flows from operations in the future, access to capital markets enabled by our strong short-term and long-term credit ratings and current borrowing availability. The Company may consider other transactions that require the issuance of additional long- and/or short-term debt or other securities to finance acquisitions, repurchase stock, refinance debt or fund other activities for general business purposes. Such transactions could require funds in excess of the Company’s current cash levels and available credit lines, and the Company’s access to or cost of such additional funds could be adversely affected by any decrease in credit ratings, which were